Rekah Pharmaceutical Industry Ltd
TASE:REKA
If you don’t study any companies, you have the same success buying stocks as you do in a poker game if you bet without looking at your cards.
Utilize notes to systematically review your investment decisions. By reflecting on past outcomes, you can discern effective strategies and identify those that underperformed. This continuous feedback loop enables you to adapt and refine your approach, optimizing for future success.
Each note serves as a learning point, offering insights into your decision-making processes. Over time, you'll accumulate a personalized database of knowledge, enhancing your ability to make informed decisions quickly and effectively.
With a comprehensive record of your investment history at your fingertips, you can compare current opportunities against past experiences. This not only bolsters your confidence but also ensures that each decision is grounded in a well-documented rationale.
Do you really want to delete this note?
This action cannot be undone.
| 52 Week Range |
1 167
1 679
|
| Price Target |
|
We'll email you a reminder when the closing price reaches ILS.
Choose the stock you wish to monitor with a price alert.
This alert will be permanently deleted.
Rekah Pharmaceutical Industry Ltd
Other Current Liabilities
Rekah Pharmaceutical Industry Ltd
Other Current Liabilities Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Other Current Liabilities | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
R
|
Rekah Pharmaceutical Industry Ltd
TASE:REKA
|
Other Current Liabilities
₪8.7m
|
CAGR 3-Years
138%
|
CAGR 5-Years
16%
|
CAGR 10-Years
24%
|
|
|
Teva Pharmaceutical Industries Ltd
TASE:TEVA
|
Other Current Liabilities
$5.2B
|
CAGR 3-Years
0%
|
CAGR 5-Years
-5%
|
CAGR 10-Years
-3%
|
|
|
Sol Gel Technologies Ltd
NASDAQ:SLGL
|
Other Current Liabilities
N/A
|
CAGR 3-Years
N/A
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
|
I
|
InterCure Ltd
TASE:INCR
|
Other Current Liabilities
₪4.1m
|
CAGR 3-Years
N/A
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
|
Mediwound Ltd
NASDAQ:MDWD
|
Other Current Liabilities
$19.9m
|
CAGR 3-Years
53%
|
CAGR 5-Years
27%
|
CAGR 10-Years
27%
|
|
|
S
|
Seach Medical Group Ltd
TASE:SEMG
|
Other Current Liabilities
₪0
|
CAGR 3-Years
N/A
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
Rekah Pharmaceutical Industry Ltd
Glance View
Rekah Pharmaceutical Industry Ltd. engages in the manufacture, import, marketing, sale, registration, and distribution of generic drugs, cosmetics, vitamins, and nutritional supplements. The firm operates two Good Manufacturing Practice (GMP) approved manufacturing sites, it has a marketing and distribution arm, a chain of pharmacies, and an export import unit. Rekah's plant covers approximately 5,000 square meters and was designed to take advantage of the most advanced and automated packaging techniques available. In April 1995, Rekah received the approval of the Ministry of Health for its new facility. The sterile department was designed to meet the standard of the United States Food and Drug Administration and was opened in February 1997. The firm distributes its products through Ophir & Shalpharm to institutional users such as Israel Health Funds, hospitals and government health facilities. Other subsidiaries include Vitamed Pharmaceutical Industry Ltd., CenterPharm, RITE, Talmor, BARBARA WOLF Ltd. and Madad.
See Also
What is Rekah Pharmaceutical Industry Ltd's Other Current Liabilities?
Other Current Liabilities
8.7m
ILS
Based on the financial report for Jun 30, 2024, Rekah Pharmaceutical Industry Ltd's Other Current Liabilities amounts to 8.7m ILS.
What is Rekah Pharmaceutical Industry Ltd's Other Current Liabilities growth rate?
Other Current Liabilities CAGR 10Y
24%
Over the last year, the Other Current Liabilities growth was -45%. The average annual Other Current Liabilities growth rates for Rekah Pharmaceutical Industry Ltd have been 138% over the past three years , 16% over the past five years , and 24% over the past ten years .
You don't have any saved screeners yet
